Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma

Xiaojing Wang, Anthony L. Sinn, Karen Pollok, George Sandusky, Shuhong Zhang, Li Chen, Jing Liang, Colin D. Crean, Attaya Suvannasankha, Rafat Abonour, Carolyn Sidor, Mark R. Bray, Sherif S. Farag

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Summary ENMD-2076 is a novel, orally-active molecule that has been shown to have significant activity against aurora and multiple receptor tyrosine kinases. We investigated the activity of ENMD-2076 against multiple myeloma (MM) cells in vitro and in vivo. ENMD-2076 showed significant cytotoxicity against MM cell lines and primary cells, with minimal cytotoxicity to haematopoietic progenitors. ENMD-2076 inhibited the phosphoinositide 3-kinase/AKT pathway and downregulated survivin and X-linked inhibitor of apoptosis as early as 6 h after treatment. With longer treatment (24-48 h), ENMD-2076 also inhibited aurora A and B kinases, and induced G2/M cell cycle arrest. In non-obese diabetic/severe combined immunodeficient mice implanted with H929 human plasmacytoma xenografts, oral treatment with ENMD-2076 (50, 100, 200 mg/kg per day) resulted in a dose-dependent inhibition of tumour growth. Immunohistochemical staining of excised tumours showed significant reduction in phospho-Histone 3 (pH3), Ki-67, and angiogenesis, and also a significant increase in cleaved caspase-3 at all dose levels compared to tumours from vehicle-treated mice. In addition, a significant reduction in p-FGFR3 was observed on Western blot. ENMD-2076 shows significant activity against MM cells in vitro and in vivo, and acts on several pathways important for myeloma cell growth and survival. These results provide preclinical rationale for clinical investigation of ENMD-2076 in MM.

Original languageEnglish (US)
Pages (from-to)313-325
Number of pages13
JournalBritish journal of haematology
Issue number3
StatePublished - Aug 2010


  • apoptosis
  • multiple myeloma
  • tyrosine kinase

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma'. Together they form a unique fingerprint.

Cite this